Drawing for TERAGENIX

USPTO serial 76373448

TERAGENIX

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
CORDOVA, RAUL
Law office
TTAB

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 604: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with TERAGENIX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Tamara Carmichael, P.A.

Hall F. McKinley, III Drew, Eckl & Farnham, LLP880 West Peachtree StreetP.O. Box 7600Atlanta, GA 30357

Goods and services

ClassDescriptionStatusFirst use
005biological agents, namely, vectors and retroviral vectors, for use in in-vitro diagnostic, biopharmaceutical, pharmaceutical and genomic industries; vector and retroviral vector manufacturing preparations, all for use in diagnostic and biopharmaceutical technology; molecular diagnostic preparations containing nucleic acids for assistance in manufacturing controls and/or reagents; and molecular and biopharmaceutical chemicals and biochemical preparations and solutions for use in the in-vitro diagnostic, biopharmaceutical, pharmaceutical and genomic industryABANDONED—
009laboratory products, medical devices and quality control products, namely, controls, calibrators, standards and panels for the in-vitro diagnostic, biopharmaceutical, pharmaceutical and genomic industriesABANDONED—
010medical diagnostic equipment, namely, diagnostic test kits and subcomponents of diagnostic test kits such as controls, calibrators, standards and reagentsABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 25, 2007MAB4ABANDONMENT NOTICE MAILED - INTER PARTES DECISION—
Jun 25, 2007ABN4ABANDONMENT - AFTER INTER PARTES DECISION—
Apr 3, 2007OP.SOPPOSITION SUSTAINED NO. 999999—
Sep 24, 2003OP.IOPPOSITION INSTITUTED NO. 999999—
Jun 17, 2003ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
May 20, 2003PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 30, 2003NPUBNOTICE OF PUBLICATION—
Mar 20, 2003CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 14, 2003CNEAEXAMINERS AMENDMENT MAILED—
Mar 6, 2003ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Jan 25, 2003CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 6, 2002CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 6, 2002MAILPAPER RECEIVED—
Jun 6, 2002CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.

Frequently asked questions

Related guidance